SIG
MTNB icon

Sargent Investment Group’s Matinas BioPharma MTNB Stock Holding History

Sargent Investment Group’s Portfolio MTNB Stock Details MTNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.79K Hold
12,720
– – ﹤0.01% 278
2026
Q1 		$6.36K Hold
12,720
– – ﹤0.01% 269
2025
Q4 		$7.45K Sell
12,720
-23,900
-65% -$28.2K ﹤0.01% 261
2025
Q3 		$69.2K Buy
36,620
+1,000
+3% +$1.44K 0.01% 118
2025
Q2 		$32.1K Sell
35,620
-6,180
-15% -$4.53K ﹤0.01% 234
2025
Q1 		$21.7K Sell
41,800
-22,400
-35% -$13.3K ﹤0.01% 231
2024
Q4 		$38.4K Sell
64,200
-16,040
-20% -$24.4K 0.01% 232
2024
Q3 		$284K Buy
80,240
+10,400
+15% +$66.2K 0.05% 171
2024
Q2 		$553K Sell
69,840
-2,370
-3% -$21.5K 0.11% 114
2024
Q1 		$978K Sell
72,210
-4,150
-5% -$49.3K 0.21% 82
2023
Q4 		$825K Sell
76,360
-2,100
-3% -$23.7K 0.18% 99
2023
Q3 		$510K Hold
78,460
– – 0.12% 115
2023
Q2 		$1.41M Sell
78,460
-6,580
-8% -$153K 0.34% 62
2023
Q1 		$2.08M Sell
85,040
-2,661
-3% -$67.2K 0.55% 44
2022
Q4 		$2.19M Buy
87,701
+3,554
+4% +$118K 0.68% 39
2022
Q3 		$2.9M Buy
84,147
+4,929
+6% +$194K 0.9% 31
2022
Q2 		$3.13M Buy
79,218
+6,338
+9% +$242K 0.97% 29
2022
Q1 		$2.93M Buy
72,880
+302
+0.4% +$11.1K 0.74% 34
2021
Q4 		$3.67M Buy
72,578
+7,678
+12% +$410K 0.84% 31
2021
Q3 		$4.22M Buy
64,900
+21,012
+48% +$907K 1.02% 30
2021
Q2 		$1.7M Buy
43,888
+3,708
+9% +$159K 0.4% 48
2021
Q1 		$2.11M Buy
40,180
+11,589
+41% +$777K 0.56% 41
2020
Q4 		$1.94M Buy
28,591
+13,141
+85% +$609K 0.61% 36
2020
Q3 		$592K Buy
15,450
+9,159
+146% +$364K 0.22% 87
2020
Q2 		$246K Buy
6,291
+2,450
+64% +$93.9K 0.09% 129
2020
Q1 		$115K Buy
3,841
+2,724
+244% +$164K 0.05% 133
2019
Q4 		$127K Buy
+1,117
New +$64.7K 0.05% 149

Other funds holding MTNB

Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
HIW
Holos Integrated Wealth Kennett Square, Pennsylvania $214M AUM 14.99% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Sargent Investment Group's MTNB Position: Q2 2026 in Review

Sargent Investment Group held its Matinas BioPharma (MTNB) position steady in Q2 2026 at 12,720 shares worth $7.79K. The position accounts for ﹤0.01% of the portfolio, ranked #278.

Sargent Investment Group first reported a position in MTNB in Q4 2019 and has held it in 27 quarters since. The position peaked at $4.22M in Q3 2021. 25 funds tracked by Wall St. Rank hold MTNB as of Q2 2026.

  • Sargent Investment Group held 12,720 shares of Matinas BioPharma worth $7.79K as of Q2 2026.
  • Sargent Investment Group left its Matinas BioPharma share count unchanged in Q2 2026.
  • Matinas BioPharma made up ﹤0.01% of Sargent Investment Group's portfolio in Q2 2026, its #278 holding.
  • Sargent Investment Group first reported a position in Matinas BioPharma in Q4 2019 and has held it in 27 quarters since.
  • Sargent Investment Group's Matinas BioPharma position peaked at $4.22M in Q3 2021.
  • 25 funds tracked by Wall St. Rank held Matinas BioPharma as of Q2 2026.

Based on Sargent Investment Group's 13F filing for Q2 2026, filed 11 Aug 2026.